Entrada Therapeutics Inc TRDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
Trading Information
- Previous Close Price
- $6.34
- Day Range
- $6.19–6.55
- 52-Week Range
- $4.93–16.45
- Bid/Ask
- $5.60 / $8.00
- Shares Outstanding
- 38.82M
- Market Cap
- $250.78M
- Volume/Avg
- 513,746 / 442,341
Key Statistics
- Price/Earnings (Normalized)
- 8.51
- Price/Sales
- 49.91
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 152
- Website
- https://www.entradatx.com
Valuation
|
Metric
|
TRDA
|
|---|---|
Price/Earnings (Normalized) | 7.98 |
Price/Book Value | 0.93 |
Price/Sales | 46.79 |
Price/Cash Flow | — |
Price/Earnings
TRDA
Financial Strength
|
Metric
|
TRDA
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 13.90 |
Interest Coverage | — |
Quick Ratio
TRDA
Profitability
|
Metric
|
TRDA
|
|---|---|
Return on Assets (Normalized) | −36.61% |
Return on Equity (Normalized) | −44.01% |
Return on Invested Capital (Normalized) | −41.82% |
Return on Assets
TRDA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|HcNm#sf | LOCK|^X@<& | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|GMvkK!^ | LOCK|#?#c! | $71B | |||
| argenx SE ADR
ARGX
| LOCK|tk&>bK | LOCK|V> | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#sP!CS | LOCK|qg | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$Lz<?> | LOCK|Kc>j# | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>lF%&rlx | LOCK|gN$% | $26B | |||
| Moderna Inc
MRNA
| LOCK|^q#xXP | LOCK|J%N | $24B | |||
| Incyte Corp
INCY
| LOCK|Z!CR<T? | LOCK|$c | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|pkrf>gY | LOCK|y?Y | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|s?Y@%#C | LOCK|J> | $16B |
United States